VMD Stock Analysis: Buy, Sell, or Hold?
VMD - Viemed Healthcare, Inc. Common Shares
$8.85
0.28 (3.27%)
▲
5d:
-3.8%
30d:
-24.16%
90d:
-8.1%
HOLD
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 03, 2026
0d
Get Alerted When VMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: VMD shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: VMD shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$17.61
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$10.94
19.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: VMD is currently trading at $8.85, which is considered oversold relative to its 30-day fair value range of $9.23 to $11.90. The stock's valuation (Forward PE: 14.9) is in line with its historical norms (15.2). Remarkably, the market is currently pricing in an annual earnings decline of 0.8% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, VMD is in a uptrend. Immediate support is located at $8.51, while resistance sits at $9.86. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: VMD scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.00 (+24.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, VMD is in a uptrend. Immediate support is located at $8.51, while resistance sits at $9.86. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: VMD scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.00 (+24.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$9.23 -
$11.90
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
96.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.3%)
- BULLISH: Trading 24.3% below Wall St target ($11.00)
- CAUTION: Bottoming setup, but lagging the sector by 25% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$9.23 -
$11.90
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.68
(7.7%)
Support & Resistance Levels
Support Level
$8.51
Resistance Level
$9.86
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.87
Wall Street Target
$11.00
(+24.3%)
Revenue Growth (YoY)
23.9%
Earnings Growth (YoY)
-12.4%
Profit Margin
4.8%
Valuation Discount vs History
-0.8% cheaper
PE vs Historical
14.9 vs 15.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.8%
(market-implied from PE analysis)
1-Year Target
$8.78
(-1%)
2-Year Target
$8.71
(-2%)
3-Year Target
$8.64
(-2%)
3-Yr Target (if PE normalizes)
(PE: 15→15)
$8.83
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 40.0%)
$32.77
(+270%)
Base:
(SPY PE: 14.9, Growth: 40.0%)
$24.28
(+174%)
Bear:
(PE: 12.6, Growth: 40.0%)
$20.64
(+133%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (25x PE), but valuation improves significantly next year (15x PE) as earnings recover.
Trailing PE: 25.21 | Current EPS (TTM): $0.34
Bull Case
$16.50
(+86%)
Analyst growth 75.0%, PE expands to 27.7
Base Case
$15.00
(+70%)
Market implied 75.0%, PE stable at 25.2
Bear Case
$5.83
(-34%)
Severe decline -20.0%, PE contracts to 21.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.9 to 15.2
Stabilization Target:
$9.04
(+2.2%)
PE Expansion Potential:
+2.2%
Share & Embed Analysis
Last updated: August 23, 2026 6:31 AM ET
Data refreshes hourly during market hours. Next update: 7:31 AM
Data refreshes hourly during market hours. Next update: 7:31 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VMD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Michael Moore
SELL
65000 shares
2026-03-20
Michael Moore
SELL
40232 shares
2026-03-19
Michael Moore
SELL
31570 shares
2026-03-18
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SYK
Stryker Corporation |
BUY
32 analysts |
$383 | 53 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 48 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 31 SELL |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$119 | 37 SELL |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 49 HOLD |
